Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

Adipose Modulation of ABCG1 Uncovers an Intimate Link Between Sphingomyelin and Triglyceride Storage

  1. Andrew J. Murphy1 and
  2. Laurent Yvan-Charvet2⇑
  1. 1Baker IDI Heart and Diabetes Institute, Melbourne, Australia
  2. 2Institut National de la Santé et de la Recherche Médicale U1065, Centre Mediterranéen de Médecine Moléculaire, Nice, France
  1. Corresponding author: Laurent Yvan-Charvet, laurent.yvan-charvet{at}unice.fr.
Diabetes 2015 Mar; 64(3): 689-692. https://doi.org/10.2337/db14-1553
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

In the early 1980s, it was established that adipose tissue not only plays an important role in triglyceride storage but also accounts for approximately 25% of total body cholesterol in humans (1). However, in obese individuals this proportion of cholesterol can increase to well over half and could contribute to adipocyte dysfunction and obesity-mediated metabolic syndrome, including low levels of plasma HDL cholesterol (1–4). Consistent with the view that adipose tissue behaves as a cholesterol sink, and its accumulation is proportional to triglycerides in response to nutritional changes to maintain cellular integrity and to regulate cellular hypertrophy, it is not surprising that adipocytes have developed a unique ability to deal with cholesterol (1). It may be for this reason that adipocytes have evolved with an extremely limited capacity to perform de novo cholesterol synthesis (1) but possess multiple strategies to extract cholesterol from circulating lipoproteins (5,6). Despite cholesterol being delivered as cholesteryl ester in adipocytes, approximately 95% of cholesterol paradoxically exists as free cholesterol (FC) (7) and resides in the plasma membrane or the cytosolic interface of lipid droplets where it is readily available for mobilization (8). Cholesterol mobilization involves adipose tissue ATP-binding cassette transporter A1 (ABCA1), which has recently been shown to contribute to HDL biogenesis in vivo (9,10). These findings illustrate an exquisite balance between adipose tissue cholesterol storage and plasma HDL cholesterol concentration and raise the question about the role that HDL cholesterol plays in obesity and associated metabolic complications.

ATP-binding cassette transporters ABCA1 and ABCG1 primarily mediate the efflux of cholesterol from peripheral cells. These transporters promote unidirectional cholesterol efflux to lipid-poor apolipoprotein A-I (apoA-I), apoE, or HDL particles, respectively, and are under the transcriptional control of liver X receptors (LXRs), master intracellular sensors that are activated in response to cholesterol biosynthetic intermediates and oxysterols (11,12). This contrasts to scavenger receptor class B type I (SR-BI), which is not an LXR target and facilitates the bidirectional flux of cholesterol depending on the cholesterol status of the cells (11). Remarkably, HDL cholesterol transport machinery is highly represented in adipocytes (5,6,13) but the relevance to obesity and metabolic complications remains poorly understood. While LXR-deficient mice are leaner than littermate controls and are protected against diet-induced obesity, the mechanisms that control fat loss in these mice are still a matter of debate and could involve either reduced lipogenesis, enhanced lipid oxidation and lipolysis, or reduced cholesterol efflux pathways (14). Consistent with apoE being an LXR target gene in adipocyte (13), apoE-deficient mice also exhibit a lean phenotype and are resistant to diet-induced obesity (15–17). However, the interpretation of this phenotype can be confounded by the fact that apoE plays a dual role promoting cholesterol efflux and mediating lipoprotein clearance (15–17) similar to SR-BI (5,6,11). LXRs also transcriptionally regulate the cholesterol efflux transporters ABCA1 and ABCG1, and deficiency of ABCA1 is associated with decreased body weight (18), while ABCG1 deficiency protects against diet-induced obesity (19). Altogether these studies point to an overall consensus in which a defective cholesterol efflux pathway is associated with reduced fat storage, an effect that could be attributed to adipose cachexia (20). However, recent studies suggest that myeloid-specific ABCA1 deletion does not alter diet-induced obesity (21), and paradoxically, specific adipocyte ABCA1 deficiency leads to increased body weight gain and fat storage in response to diet-induced obesity due to adipose cholesterol accumulation altering lipolysis (22) (Fig. 1). These complex findings emphasize the need for a more nuanced understanding of how cholesterol efflux pathways affect adipose function.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Hypothetical model for ABCA1 and ABCG1 regulation of adipose fat storage. A: At steady state, 95% of cholesterol exists as FC and is in equilibrium with triglycerides (TG). The relation of FC and TG to SM content is not known. B: Removal of adipocyte FC by ABCA1-mediated FC efflux leads to lipolysis by an unknown mechanism to maintain the proper ratio of FC and TG for cellular integrity and cell size. C: ABCG1-mediated SM efflux is now associated with reduced plasma membrane SM content, a sphingolipid known to be a strong inhibitor of LPL, leading to adipocyte TG storage.

In this issue, Frisdal et al. (23) use a number of in vitro and in vivo approaches along with data from people carrying single nucleotide polymorphisms associated with increased ABCG1 expression to put forward the idea that deletion of adipose ABCG1 is responsible for the protection against adiposity as seen in the global Abcg1−/− mice (19). To test their hypothesis in vivo, the authors developed an innovative approach of a local injection of Abcg1 short hairpin RNA lentiviral particles into the epididymal fat pads of mice. While one of the caveats of this approach could be the targeting of adipose macrophages, the authors were keen to show that deletion of ABCG1 in adipose tissue led to reduced inflammation, inconsistent with a major targeting of Abcg1 in macrophages promoting an inflammatory response (12) but consistent with reduced adipocyte fat storage (23). Future studies will be needed to elucidate the molecular mechanisms as reduced adipocyte inflammation has also been recently observed in apoA-I transgenic mice (24). Several mechanisms could be considered. First, reduced cellular cholesterol was observed in both studies and could reflect reduced proinflammatory sterols in adipocytes or a shunt into production of anti-inflammatory sterols such as desmosterol (12). Second, modulation of fatty acid metabolism−related genes observed in ABCG1-deficient adipocytes could be linked to lower inflammation and/or decreased transcriptional responses of nuclear factor-κβ target genes as a result of altered histone acetylation in their enhancer/promoter regions (12). Third, modulation of fatty acid oxidation (especially enhanced activity of the uncoupling protein 1 [UPC1]) as observed in LXR knockout mice (14) could lead to adipose tissue browning. Finally, the impact of enhanced cellular sphingomyelin (SM) content on adipocyte inflammation in ABCG1-deficient adipocytes still needs to be elucidated.

In contrast to a previous report (9), Frisdal et al. claim that ABCG1 contributes to adipose cholesterol efflux even though this mechanism does not appear to drive their phenotype, as adipose ABCG1 deficiency was associated with lower cellular cholesterol content independent of any change in ABCA1 expression or apoE secretion in adipocytes. This contrasted with the adipose cholesterol accumulation observed in adipose ABCA1 deficiency driving an upregulation of LXR target genes such as ABCG1 (21). So, this raises the question: Where did the cholesterol go in ABCG1-deficient adipocytes? As cholesterol synthesis is extremely low in adipocytes, it is most likely that alternative cholesterol efflux pathways are taking place in these cells. As ABCG1 appears to promote movement of cholesterol from the endoplasmic reticulum to the plasma membrane to release sterols more readily to extracellular lipoprotein acceptors (12), it is tempting to speculate that cholesterol trafficking is diverted to lysosomal pathways at the expense of the endoplasmic reticulum–like structure surrounding lipid droplets in ABCG1-deficient adipocytes (8). This could explain the higher lipid raft visualization in these cells despite reduced cellular cholesterol and triglyceride content (23). Further studies are required to better comprehend cholesterol trafficking in adipocytes and the interplay between ABCA1, ABCG1, and SR-BI in adipocyte cholesterol efflux.

Perhaps the most intriguing finding in this study is the role of ABCG1 mediating SM efflux in adipocytes. One previous model based on transfected cells suggested that the ability of ABCG1 to promote SM efflux could lead to such an extensive change in the equilibrium of membrane components that the outer leaflet becomes more attractive to sterol efflux (25). Frisdal et al. (23) translate this concept in a more physiological context by showing that defective ABCG1-mediated SM efflux could be a primary function of this transporter in adipocytes with pathological consequences on cholesterol efflux and adipose functions. Because SM avidly binds cholesterol, accumulation of intracellular SM in ABCG1-deficient adipocytes could also prevent cholesterol transport from lysosomes to the plasma membrane further contributing to reduce cholesterol efflux (26). However, reduced cellular cholesterol content was observed in ABCG1-deficient adipocytes, suggesting that accumulation of SM occurred at the level of the plasma membrane in these cells (23). Jiang and colleagues (27) have previously reported that reduced plasma membrane SM prevented fat storage by enhancing adipose tissue insulin sensitivity. The current study rather proposes that part of the reduced triglyceride storage in ABCG1-deficient adipocytes could result from enhanced plasma membrane SM content preventing lipoprotein lipase (LPL) activity (Fig. 1). This was illustrated by showing that SM depletion by sphingomyelinase rescued not only LPL activity but also the fat loss of ABCG1-deficient adipocytes, while specific removal of cholesterol by cyclodextrin had no impact.

A possible involvement of ABCG1 in preventing human adipose fat regulation is illustrated in the current study through human genetics (23). A beneficial association between body fatness and triglycerides was also previously reported for both ABCA1 and apoE loss of function (28,29). However, because both LXRα gain of function and LXRβ loss of function could be associated with obesity (for review, see 14), more studies are required to elucidate the complex interactions between cholesterol efflux pathways and adipocyte plasticity and functions in humans. Perhaps one intervention that is of more immediate relevance is the contribution of cholesteryl ester transfer protein (CEPT) inhibitors, which raise endogenous HDL, as results from phase III clinical trials are expected soon. For instance, it will be important to determine the relevance of the pathway identified by Frisdal et al. (23) in the presence of CETP as mice do not express it and transgenic mice overexpressing CETP exhibit reduced adipose fat storage (30).

Article Information

Funding. This work was supported by grants from INSERM ATIP-AVENIR, L’Agence Nationale de la Recherche, and the Fondation de France to L.Y.-C. and a Viertel award from Diabetes Australia Research Trust and a National Health and Medical Research Council program grant (APP10363652) to A.J.M.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 840.

  • © 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

References

  1. ↵
    1. Krause BR,
    2. Hartman AD
    . Adipose tissue and cholesterol metabolism. J Lipid Res 1984;25:97–110pmid:6368715
    OpenUrlAbstract
    1. Yu BL,
    2. Zhao SP,
    3. Hu JR
    . Cholesterol imbalance in adipocytes: a possible mechanism of adipocytes dysfunction in obesity. Obes Rev 2010;11:560–567pmid:20025694
    OpenUrlCrossRefPubMed
    1. Le Lay S,
    2. Ferré P,
    3. Dugail I
    . Adipocyte cholesterol balance in obesity. Biochem Soc Trans 2004;32:103–106pmid:14748723
    OpenUrlCrossRefPubMed
  2. ↵
    1. Montoye HJ,
    2. Epstein FH,
    3. Kjelsberg MO
    . Relationship between serum cholesterol and body fatness. An epidemiologic study. Am J Clin Nutr 1966;18:397–406pmid:5938192
    OpenUrlAbstract
  3. ↵
    1. Fazio S,
    2. Linton MF
    . Unique pathway for cholesterol uptake in fat cells. Arterioscler Thromb Vasc Biol 2004;24:1538–1539pmid:15345518
    OpenUrlFREE Full Text
  4. ↵
    1. Yvan-Charvet L,
    2. Bobard A,
    3. Bossard P, et al
    . In vivo evidence for a role of adipose tissue SR-BI in the nutritional and hormonal regulation of adiposity and cholesterol homeostasis. Arterioscler Thromb Vasc Biol 2007;27:1340–1345pmid:17363694
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Schreibman PH,
    2. Dell RB
    . Human adipocyte cholesterol. Concentration, localization, synthesis, and turnover. J Clin Invest 1975;55:986–993pmid:1123433
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Prattes S,
    2. Hörl G,
    3. Hammer A, et al
    . Intracellular distribution and mobilization of unesterified cholesterol in adipocytes: triglyceride droplets are surrounded by cholesterol-rich ER-like surface layer structures. J Cell Sci 2000;113:2977–2989pmid:10934037
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Zhang Y,
    2. McGillicuddy FC,
    3. Hinkle CC, et al
    . Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 2010;121:1347–1355pmid:20212278
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Chung S,
    2. Sawyer JK,
    3. Gebre AK,
    4. Maeda N,
    5. Parks JS
    . Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo. Circulation 2011;124:1663–1672pmid:21931081
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Rosenson RS,
    2. Brewer HB Jr.,
    3. Davidson WS, et al
    . Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012;125:1905–1919pmid:22508840
    OpenUrlFREE Full Text
  10. ↵
    1. Tall AR,
    2. Yvan-Charvet L
    . Cholesterol in inflammation and immune function. Nat Immunol. In press
  11. ↵
    1. Laffitte BA,
    2. Repa JJ,
    3. Joseph SB, et al
    . LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 2001;98:507–512pmid:11149950
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Laurencikiene J,
    2. Rydén M
    . Liver X receptors and fat cell metabolism. Int J Obes (Lond) 2012;36:1494–1502pmid:22370853
    OpenUrlPubMed
  13. ↵
    1. Huang ZH,
    2. Reardon CA,
    3. Mazzone T
    . Endogenous apoE expression modulates adipocyte triglyceride content and turnover. Diabetes 2006;55:3394–3402pmid:17130485
    OpenUrlAbstract/FREE Full Text
    1. Gao J,
    2. Katagiri H,
    3. Ishigaki Y, et al
    . Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes 2007;56:24–33pmid:17192461
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Hofmann SM,
    2. Perez-Tilve D,
    3. Greer TM, et al
    . Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-deficient mice. Diabetes 2008;57:5–12pmid:17914034
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Orsó E,
    2. Broccardo C,
    3. Kaminski WE, et al
    . Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice. Nat Genet 2000;24:192–196pmid:10655069
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Buchmann J,
    2. Meyer C,
    3. Neschen S, et al
    . Ablation of the cholesterol transporter adenosine triphosphate-binding cassette transporter G1 reduces adipose cell size and protects against diet-induced obesity. Endocrinology 2007;148:1561–1573pmid:17194745
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Gautier EL,
    2. Westerterp M,
    3. Bhagwat N, et al
    . HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med 2013;210:339–353pmid:23319699
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Zhu X,
    2. Chung S,
    3. Bi X, et al
    . Myeloid cell-specific ABCA1 deletion does not worsen insulin resistance in HF diet-induced or genetically obese mouse models. J Lipid Res 2013;54:2708–2717pmid:23894207
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. de Haan W,
    2. Bhattacharjee A,
    3. Ruddle P,
    4. Kang MH,
    5. Hayden MR
    . ABCA1 in adipocytes regulates adipose tissue lipid content, glucose tolerance, and insulin sensitivity. J Lipid Res 2014;55:516–523pmid:24443560
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Frisdal E, Le Lay S, Hooton H, et al. Adipocyte ATP-binding cassette G1 promotes triglyceride storage, fat mass growth, and human obesity. Diabetes 2015;64:840–855
  21. ↵
    1. Umemoto T,
    2. Han CY,
    3. Mitra P, et al
    . Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1. Circ Res 2013;112:1345–1354pmid:23501697
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Kobayashi A,
    2. Takanezawa Y,
    3. Hirata T, et al
    . Efflux of sphingomyelin, cholesterol, and phosphatidylcholine by ABCG1. J Lipid Res 2006;47:1791–1802pmid:16702602
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Leventhal AR,
    2. Chen W,
    3. Tall AR,
    4. Tabas I
    . Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux. J Biol Chem 2001;276:44976–44983pmid:11579092
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Li Z,
    2. Zhang H,
    3. Liu J, et al
    . Reducing plasma membrane sphingomyelin increases insulin sensitivity. Mol Cell Biol 2011;31:4205–4218pmid:21844222
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Srinivasan SR,
    2. Li S,
    3. Chen W,
    4. Boerwinkle E,
    5. Berenson GS
    . R219K polymorphism of the ABCA1 gene and its modulation of the variations in serum high-density lipoprotein cholesterol and triglycerides related to age and adiposity in white versus black young adults. The Bogalusa Heart Study. Metabolism 2003;52:930–934pmid:12870173
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Pouliot MC,
    2. Després JP,
    3. Moorjani S,
    4. Lupien PJ,
    5. Tremblay A,
    6. Bouchard C
    . Apolipoprotein E polymorphism alters the association between body fatness and plasma lipoproteins in women. J Lipid Res 1990;31:1023–1029pmid:2373952
    OpenUrlAbstract
  27. ↵
    1. Zhou H,
    2. Li Z,
    3. Hojjati MR, et al
    . Adipose tissue-specific CETP expression in mice: impact on plasma lipoprotein metabolism. J Lipid Res 2006;47:2011–2019pmid:16751623
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Diabetes: 64 (3)

In this Issue

March 2015, 64(3)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Adipose Modulation of ABCG1 Uncovers an Intimate Link Between Sphingomyelin and Triglyceride Storage
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Adipose Modulation of ABCG1 Uncovers an Intimate Link Between Sphingomyelin and Triglyceride Storage
Andrew J. Murphy, Laurent Yvan-Charvet
Diabetes Mar 2015, 64 (3) 689-692; DOI: 10.2337/db14-1553

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Adipose Modulation of ABCG1 Uncovers an Intimate Link Between Sphingomyelin and Triglyceride Storage
Andrew J. Murphy, Laurent Yvan-Charvet
Diabetes Mar 2015, 64 (3) 689-692; DOI: 10.2337/db14-1553
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
  • There Is Something About Insulin Granules
  • Metabolic Flexibility of Mitochondria Plays a Key Role in Balancing Glucose and Fatty Acid Metabolism in the Diabetic Heart
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.